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==========================

The application of percutaneous coronary intervention (PCI) as a treatment option is increasing in patients with unstable angina in China. During the procedure of PCI, intravenous unfractionated heparin (UFH) is mainly used as the standard anticoagulant in the catheterization laboratory, needing dose adjustment for activated clotting time (ACT).\[[@ref1][@ref2]\] Most domestic centers with interventional cardiology facilities would choose classical UFH at first. In fact, UFH sometimes has unstable and unpredictable effects on coagulation; the low therapeutic window of UFH leads to potential drug-induced thrombocytopenia and high risk of bleeding; the half-life is short (1 h), and the ACT should be closely observed in patients.\[[@ref3]\] It is necessary to suggest a better anticoagulation drug or plan for PCI.

Enoxaparin, a low-molecular-weight heparin, has anticoagulant and antithrombotic effects during PCI with no need of repeatedly monitoring ACT due to its longer half-life (3.5--4.5 h). In the past, due to induction of thrombosis and even abrupt vessel closure, there were some limitations for intravenous enoxaparin alone applying to PCI patients. Recently, studies have shown that enoxaparin is able to reduce the risk of bleeding and it has similar safety and efficacy compared to UFH in PCI patients.\[[@ref3][@ref4][@ref5][@ref6]\] Although enoxaparin has been accepted as a guideline-recommended Class IIA and first-line therapy since many years ago,\[[@ref7]\] there are still many concerns for doctors in China. In our ward, we once used enoxaparin alone according to the guidelines and found a little catheter thrombosis during PCI. Considering the above studies and clinical experiences of our team, we suggest a new anticoagulation strategy of UFH in combination with sequential enoxaparin, using UFH 3000 U plus enoxaparin 0.75 mg/kg per patient. In clinical practice, we observed that the strategy showed obvious advantages in PCI patients with transfemoral approach; it significantly shortened the bedridden time (at least 24 h) and potentially reduced the bleeding complications and medical consumption (for instance, nursing time). We have performed it in our center since 2003, and the low mortality and complications have probably confirmed its clinical safety and efficacy. This study evaluated the efficacy and safety of UFH with sequential enoxaparin, as compared with UFH, on PCI patients with complex coronary artery lesions.

M[ETHODS]{.smallcaps} {#sec1-2}
=====================

Ethical approval {#sec2-1}
----------------

This study complied with the *Declaration of Helsinki* and local regulations, and it was authorized by the Ethics Committee of Beijing Anzhen Hospital. Informed consent was obtained from all individual participants included in the study.

Subjects {#sec2-2}
--------

Between January 2015 and April 2017, we retrospectively consecutively identified the medical records of PCI patients who received UFH with sequential enoxaparin (600) or UFH alone (600) at the same time in our institution. Eligible participants were at least older than 18 years. Entry criteria also included: patients with a final diagnosis of unstable angina pectoris and having complex coronary artery lesions confirmed by coronary angiography. The diagnosis of unstable angina was based on clinical histories, physical examinations, and documentation of ischemia-like electrocardiogram (ECG) changes. The ECG changes were defined as ST-segment depression of at least 0.1 mV (including reciprocal changes) or T-wave inversion of at least 0.1 mV in ≥2 contiguous leads. Patients' vessel lesions were considered "complex" according to the previous studies\[[@ref8][@ref9]\] when any of the following symptoms were present: ostial lesion, unprotected left main coronary artery lesion, bifurcation lesion, more than two vessels treated, lesion length \>27 mm, totally occluded lesion (defined as the thrombolysis in myocardial infarction \[TIMI\] grade 0 flow and lasting ≥3 months), any lesion with thrombus, in-stent restenosis lesion, saphenous vein graft lesion, arterial bypass graft lesion, etc. Patients were excluded when they had any of the following major criteria: acute myocardial infarction (MI), overt congestive heart failure, severe arrhythmia, pericarditis, symptoms of aortic dissection, pregnancy, severe renal or hepatic diseases, malignant disease, history of a cerebrovascular accident, neutropenia or thrombocytopenia, known allergy to the study drugs, recent major surgery, life-limiting major concomitant noncardiac diseases, etc.

Anticoagulation procedures {#sec2-3}
--------------------------

The included 1200 patients who need PCI after initial angiography would be treated with either UFH with sequential enoxaparin (*n* = 600) or UFH alone (*n* = 600) in the catheterization laboratory. The observation group was given an initial intravenous dose of 3000 U of UFH plus additional intravenous enoxaparin at a dose of 0.75 mg/kg. The control group was given intravenous UFH at a dose of 100 U/kg, with dose adjustment according to activated clotting time (ACT) during PCI. Before PCI, a total dose of aspirin (300 mg) and clopidogrel (600 mg) was administered for all patients if no contraindication was present, according to local practice.

PCI was performed according to the current standard techniques. The intraoperative device, pharmacotherapy use, and interventional strategy were decided by an operator. All patients had the second-generation drug-eluting stents. For the observation group, patients did not need ACT monitoring and the sheath could be removed immediately at the end of the procedure of PCI (no more than 2 h). For the control group, if the operation time lasted over 1 h, necessitating additional dose of UFH was at the discretion of the operator to achieve a target ACT of 300--350 s during PCI. For patients undergoing transfemoral approach, arterial closure devices were allowed according to the patients' willing but not free in China. After PCI, all patients were recommended lifelong aspirin and clopidogrel therapy for at least 12 months.

Measurements and endpoints {#sec2-4}
--------------------------

The measurements included baseline demographic, clinical, angiographic, and procedural characteristics. All patients were followed up at 30 days and 1 year by telephonic interview or office visits. Clinical data during hospitalization and events during follow-up were adjudicated by source documentation by independent physicians blinded to the objectives of the study. The safety endpoints were the occurrence of bleeding events and transfusion during hospitalization within 48 h after PCI. Bleeding was stratified according to the TIMI criteria from Chesebro *et al*.\'s study.\[[@ref10]\] The primary endpoints were major adverse cardio-cerebrovascular events (MACCE) and repeat angina within 30 days after PCI. MACCE included a composite of all-cause death, recurrent MI, cerebrovascular event, and urgent target vessel revascularization (TVR). All-cause death was defined as death from many causes, including cardiac and noncardiac events. MI was defined as an elevation of troponin over the upper range limit satisfying at least the following one: symptoms of cardiac ischemia, new ischemic ECG changes, or ECG\'s development of pathologic Q-waves.\[[@ref11]\] TVR was defined as repeat revascularization of the target lesion and target vessel proximal to the stent site. Cerebrovascular accident was defined as either a transient ischemic attack or a stroke, which would be diagnosed by a neurologist. The secondary endpoint was MACCE and repeat angina within 1 year after PCI.

Statistical analysis {#sec2-5}
--------------------

All statistical analysis was performed with SPSS 18.0 (SPSS Inc., Chicago, IL, USA). Continuous variables were presented as mean ± standard deviation (SD) and analyzed by the Student\'s *t*-test or Wilcoxon rank-sum test if necessary. Data distribution of patients was tested for normality using the Kolmogorov--Smirnov test. Categorical variables were expressed as frequencies and percentages and analyzed by the Chi-square or Fisher\'s exact tests if necessary. For the safety endpoints, the multivariate logistic regression adjusted for covariates was used to compare the incidence of TIMI bleeding and transfusion between groups. The multivariate Cox proportional hazard model was used to analyze the 30-day and 1-year events, with adjustment for covariates. Patients were divided into subgroups by the transfemoral approach and transradial approach. All *P* values and 95% confidence intervals were two-sided. A value of *P* \< 0.05 was considered statistically significant.

R[ESULTS]{.smallcaps} {#sec1-3}
=====================

Patient characteristics {#sec2-6}
-----------------------

A total of 1200 eligible patients were finally included: 600 patients received 3000 U of UFH plus 0.75 mg of enoxaparin per kilogram intravenously and 600 patients received 100 U of UFH per kilogram intravenously. Follow-up was not available in all patients. During 30-day follow-up, 131 were not eligible for inclusion: 83 were lost to contact after several attempts, and 48 were unwilling or unknown to answer the questions, giving a follow-up rate of 89.1%. During 1-year follow-up, 179 were lost: 110 were lost to contact, and 69 were unwilling to reply, giving a follow-up rate of 85.1%.

Baseline characteristics of the patients are summarized in [Table 1](#T1){ref-type="table"}. The mean age was 59.5 years and 75.8% (909) of the patients were men. As shown in [Table 1](#T1){ref-type="table"}, patients in the observation group were older and they showed higher prevalence or level of hypercholesterolemia, familial history, peripheral vascular disease, serum lipids, and glucose compared with the control group; however, there was no significant difference between groups. The two groups had normal left ventricular ejection fractions. Overall, the baseline characteristics of the patients were similar in the two groups.

###### 

Baseline characteristics of the control and observation groups

  Characteristics                        Control group\* (*n* = 600)   Observation group^†^ (*n* = 600)   *t* or *χ*^2^   *P*
  -------------------------------------- ----------------------------- ---------------------------------- --------------- -------
  Age (years), mean ± SD                 59.41 ± 9.53                  59.61 ± 9.35                       0.36^‡^         0.286
  Men, *n* (%)                           467 (77.8)                    442 (73.7)                         2.84^§^         0.092
  BMI (kg/m^2^), mean ± SD               26.73 ± 3.35                  26.34 ± 3.47                       −2.00^‡^        0.109
  Hypertension, *n* (%)                  407 (67.8)                    380 (63.3)                         2.69^§^         0.101
  Hypercholesterolemia, *n* (%)          86 (14.3)                     100 (16.7)                         1.25^§^         0.264
  Diabetes mellitus, *n* (%)             221 (36.8)                    193 (32.2)                         2.89^§^         0.089
  Familial history, *n* (%)              58 (9.7)                      78 (13.0)                          3.32^§^         0.069
  Previous MI, *n* (%)                   130 (21.7)                    126 (21.0)                         0.08^§^         0.778
  Previous CABG, *n* (%)                 21 (3.5)                      15 (2.5)                           1.03^§^         0.310
  Previous PCI, *n* (%)                  123 (20.5)                    117 (19.5)                         0.19^§^         0.665
  Previous stroke, *n* (%)               75 (12.5)                     64 (10.7)                          0.99^§^         0.321
  Peripheral vascular disease, *n* (%)   21 (3.5)                      25 (4.2)                           0.36^§^         0.548
  Smokers, *n* (%)                       262 (43.7)                    240 (40.0)                         1.66^§^         0.198
  Drinkers, *n* (%)                      163 (27.2)                    140 (23.3)                         2.34^§^         0.126
  TG (mmol/L), mean ± SD                 2.03 ± 1.51                   2.16 ± 1.67                        0.73^‡^         0.063
  TC (mmol/L), mean ± SD                 3.97 ± 1.10                   4.14 ± 1.16                        2.61^‡^         0.294
  LDL-C (mmol/L), mean ± SD              2.51 ± 0.93                   2.55 ± 0.96                        0.76^‡^         0.558
  HDL-C (mmol/L), mean ± SD              0.97 ± 0.37                   0.99 ± 0.25                        1.27^‡^         0.061
  Glucose (mmol/L), mean ± SD            6.32 ± 2.13                   6.55 ± 2.55                        0.84^‡^         0.203
  LVEF (%), mean ± SD                    62.31 ± 7.18                  63.56 ± 6.82                       3.09^‡^         0.864

\*UFH alone; ^†^UFH with sequential enoxaparin; ^‡^*t* value; ^§^*χ*^2^ value. BMI: Body mass index; MI: Myocardial infarction; CABG: Coronary bypass surgery; PCI: Percutaneous coronary intervention; TG: Triglyceride; TC: Total cholesterol; LDL-C: Low-density lipoprotein cholesterol; HDL-C: High-density lipoprotein cholesterol; LVEF: Left ventricular ejection fraction; UFH: Unfractionated heparin; SD: Standard deviation.

The angiographic and procedural characteristics of the two groups are shown in [Table 2](#T2){ref-type="table"}. The complexity of coronary artery lesions and number of vessel lesions per patient showed no difference between groups. Patients in the observation group had less stent implantation per patient than the control group (2.13 vs. 2.25, *P* = 0.002), and each patient in both groups was treated with at least two stents. A percentage of 11.5% of all patients underwent primary PCI via the transfemoral approach, which was obviously not used as the first option. Intraprocedural complications were low and similar between groups. The PCI success was achieved in 94.8% of all patients with complex lesion morphology.

###### 

Angiographic and procedural characteristics of the control and observation groups

  Characteristics                                   Control group\* (*n* = 600)   Observation group^†^ (*n* = 600)   *t* or *χ*^2^   *P*
  ------------------------------------------------- ----------------------------- ---------------------------------- --------------- -------
  Lesion characteristics, *n* (%)                                                                                                    
   Ostial lesion                                    9 (1.5)                       8 (1.3)                            0.06^‡^         0.807
   Bifurcation lesion                               69 (11.5)                     67 (11.2)                          0.03^‡^         0.855
   Left main lesion                                 17 (2.8)                      13 (2.2)                           0.55^‡^         0.460
   Multivessel lesion (*n* ≥2)                      272 (45.3)                    258 (43.0)                         0.66^‡^         0.416
   Diffuse and long lesion                          234 (39.0)                    207 (34.5)                         2.61^‡^         0.106
   In-stent restenosis                              60 (10.0)                     65 (10.8)                          0.22^‡^         0.637
   Calcified lesion (with rotational atherectomy)   8 (1.3)                       9 (1.5)                            0.06^‡^         0.807
   Total occlusion                                  155 (25.8)                    176 (29.3)                         1.84^‡^         0.175
   Thrombus-containing lesion                       12 (2.0)                      6 (1.0)                            2.03^‡^         0.154
   Saphenous vein graft                             21 (3.5)                      15 (2.5)                           1.03^‡^         0.310
  Procedural characteristics                                                                                                         
   Number of narrowed coronary vessels, mean ± SD   1.62 ± 0.75                   1.58 ± 0.78                        −0.87^§^        0.575
   Number of stents per patient, mean ± SD          2.25 ± 1.45                   2.13 ± 1.31                        −1.43^§^        0.002
   Stent length (mm), mean ± SD                     22.58 ± 5.82                  22.25 ± 5.58                       −1.00^§^        0.288
   Stent diameter (mm), mean ± SD                   2.97 ± 0.45                   2.92 ± 0.45                        −1.61^§^        0.193
   Catheter thrombosis, *n* (%)                     0 (0.0)                       0 (0.0)                            --              --
   Final TIMI 3 flow, *n* (%)                       562 (93.7)                    561 (93.5)                         0.01^‡^         0.906
   Transfemoral approach, *n* (%)                   70 (11.7)                     68 (11.3)                          0.03^‡^         0.856
   PCI success, *n* (%)                             564 (94.0)                    573 (95.5)                         1.36^‡^         0.244

\*UFH alone; ^†^UFH with sequential enoxaparin; ^‡^*χ*^2^ value; ^§^*t*-value. --: Not applicable; TIMI: Thrombosis in myocardial infarction; PCI: Percutaneous coronary intervention; UFH: Unfractionated heparin; SD: Standard deviation.

Clinical outcomes {#sec2-7}
-----------------

The clinical outcomes of 48 h, 30 days, and 1 year are listed in [Table 3](#T3){ref-type="table"}. The major and minor TIMI bleeding during the first 48 h occurred in 3.3% of patients in the observation group and 4.7% of patients in the control group; no obvious difference was demonstrated between groups. No transfusion was found in the observation and control groups, respectively. In [Table 3](#T3){ref-type="table"}, we primarily paid attention to the endpoints in 30-day follow-up. The rate of MACCE was 0.9% in the observation group and 1.5% in the control group, and the difference was not significant between them. No significant difference was found in the incidences of all-cause death, MI, TVR, and cerebrovascular event. Angina rate was 2.8% in the observation group and 3.3% in the control group, which still showed insignificant difference (*P* = 0.613).

###### 

Clinical outcomes of the control and observation groups

  Events                   Control group\* (*n* = 600)   Observation group^†^ (*n* = 600)   *P*
  ------------------------ ----------------------------- ---------------------------------- ----------
  48 h, *n* (%)            *n* = 600                     *n* = 600                          
   TIMI bleeding           28 (4.7)                      20 (3.3)                           0.258^‡^
   Major                   10 (1.7)                      5 (0.8)                            0.199^‡^
   Minor                   18 (3.0)                      15 (2.5)                           0.606^‡^
   Transfusion             0 (0.0)                       0 (0.0)                            --
  30 days, *n* (%)         *n* = 538                     *n* = 531                          
   All-cause death         0 (0.0)                       0 (0.0)                            --
   Myocardial infarction   3 (0.6)                       2 (0.4)                            0.648^§^
   TVR                     5 (0.9)                       3 (0.6)                            0.481^§^
   Cerebrovascular event   0 (0.0)                       0 (0.0)                            --
   MACCE                   8 (1.5)                       5 (0.9)                            0.406^§^
   Angina                  18 (3.3)                      15 (2.8)                           0.613^§^
  1 year, *n* (%)          *n* = 513                     *n* = 508                          
   All-cause death         2 (0.4)                       3 (0.6)                            0.659^§^
   Myocardial infarction   6 (1.2)                       4 (0.8)                            0.528^§^
   TVR                     6 (1.2)                       5 (1.0)                            0.760^§^
   Cerebrovascular event   0 (0.0)                       1 (0.2)                            0.312^§^
   MACCE                   14 (2.7)                      13 (2.6)                           0.846^§^
   Angina                  63 (12.3)                     50 (9.8)                           0.368^§^

\*UFH alone; ^†^UFH with sequential enoxaparin; ^‡^*P* value calculated from the logistic regression model; ^§^*P* value calculated from the Cox regression model. --: Not applicable; TIMI: Thrombosis in myocardial infarction; TVR: Target vessel revascularization; MACCE: Major adverse cardio-cerebrovascular events; UFH: Unfractionated heparin.

During 1-year follow-up after PCI, total MACCE occurred in 2.6% of patients in the observation group and 2.7% in the control group; there was no significant difference between the two groups. The 1-year incidences of all-cause death, MI, TVR, and cerebrovascular event showed no significant difference between groups. Angina in the observation group was less frequent than that in the control group (9.8% vs. 12.3%, *P* = 0.368).

Due to the clinical experience that the operative approach has some influence on the rates of bleeding and MACCE, we finally performed a subgroup analysis between PCI patients with transfemoral approach and those with transradial approach. In this study, our data were unable to identify a significant difference in the above complications and events between the two subgroups (data not shown).

D[ISCUSSION]{.smallcaps} {#sec1-4}
========================

In the current study, we compared the safety and efficacy of UFH with sequential enoxaparin intravenously with that of UFH intravenously in PCI patients with complex coronary artery disease. The wide range of lesion and clinical complexity were collected to best reflect the spectrum of patients in real-world practice. As the results, for the risk of bleeding, the benefit of UFH at a dose of 3000 U plus enoxaparin at a dose of 0.75 mg/kg was not significant, as compared with UFH at a dose of 100 U/kg. UFH with sequential enoxaparin showed similar results with UFH in terms of transfusion as well as the endpoints within 30 days and 1 year.

"UFH with sequential enoxaparin" had been implemented since 2003 in our center, and approximately 600 patients per year have been benefited from the treatment. Prior domestic studies only focused on UFH or enoxaparin alone.\[[@ref12][@ref13][@ref14]\] This anticoagulation plan had been used for our patients with different severity of coronary artery lesions and operative approach. With many years' practice, we had observed that there were very low risks of in- and out-hospital complications. In this study, our team introduced the strategy\'s content to medical workers in the area of interventional cardiology, and we hoped that medical peers could take it into consideration for PCI patients in clinical practice. More high-quality clinical studies should be performed to verify the findings.

The negative results obtained between the two groups, to some extent, were not surprising and several potential explanations may account for them in the following section. The transradial approach for patients undergoing coronary catheterization is used as the first option according to local practice, and the transfemoral access is chosen when contraindications to the former are present. In our study, 88.5% of the PCI patients chose transradial approach, which is associated with lower incidence of clinical complications in comparison with transfemoral approach.\[[@ref15]\] In addition, the low-risk populations, physicians with improved coronary stent technology, standardized adjunctive pharmacotherapy, and routine use of potent antiplatelet therapy were all able to reduce the rates of clinical complications related to PCI. Our anticoagulation plan was originally designed to ease complications in patients undergoing transfemoral access. In the subgroup analysis regarding this approach, we identified no significant difference in the risk of bleeding and MACCE. However, the results should be interpreted with caution, and owing to the small number of patients between groups (68 vs. 70), the statistical power of the subgroup might be limited to detecting differences.

Compared with UFH, enoxaparin has the advantages of a more predictable anticoagulant dose response without repetitive ACT monitoring during PCI, a longer half-life (3.5--4.5 h), as well as a greater ratio of anti-factor Xa to anti-factor IIa activity, inhibiting the downstream production of many thrombin molecules.\[[@ref14][@ref16][@ref17]\] Enoxaparin can decrease activation of the platelet, release of the von Willebrand factor, and inflammation.\[[@ref18][@ref19][@ref20]\] Due to a longer half-life of enoxaparin, when using our anticoagulation plan, no additional dose of anticoagulant is needed during PCI (no more than 2 h), especially for patients with complex coronary artery lesions whose operation time generally lasts long. For such patients receiving UFH alone, additional dose is usually necessary when PCI performs over 1 h, and neglecting this step probably results in in-stent thrombosis and even serious complications. Our plan can bring about the best advantage for PCI patients via the transfemoral approach. In fact, the transfemoral approach remains the most common vascular access for PCI in many countries and patients with complex coronary artery disease, especially with totally occluded lesion. For these patients, failing or being unwilling to apply arterial closure devices, when receiving UFH alone, the femoral artery sheath cannot be immediately removed after PCI. Patients have to keep the sheath for at least 4--6 h, and sheath removal should meet the criteria that ACT is less than 180 s. The puncture point is manually pressed for 1 h and then restricted with the use of pressure bandaging for 48 h. After 72 h, the patients can leave the bed. For patients receiving our plan, the femoral artery sheath can be immediately removed after PCI. The puncture point is manually pressed for 30 min and then only restricted with the use of pressure bandaging for 24 h. The bedridden time is 48 h after PCI. These potentially reduced the bleeding complications and discomfort due to long bedridden time, such as back pain. These also decrease the clinical stress for doctors and nurses. Guidelines at abroad recommended intravenous enoxaparin alone during PCI, but we observed a little catheter thrombosis and substandard testing results of anti-Xa factor and ACT in some patients undergoing this anticoagulant scheme. In our new plan, when 3000 U UFH is used before PCI, these two indicators can reach the standard and catheter thrombosis does not appear. Finally, the effect of enoxaparin on the risk of bleeding was handled by a simpler treatment protocol than that typically used for UFH. Taken together, "UFH with sequential enoxaparin" plan should be encouraged for PCI patients. Although our study did not report significant clinical benefits over UFH using the novel strategy, it should be useful for PCI patients undergoing transfemoral approach.

Some clinical studies in PCI patients found that cross-anticoagulation might increase the bleeding risk and it is not well recommended.\[[@ref21][@ref22]\] In these studies, the PCI patients received different anticoagulation before operation, during operation and after operation at the time of hospitalization, which was not consistent with the anticoagulation option in the present study and might affect the bleeding risk. For our study, preoperative, intraoperative, and postoperative options related to anticoagulation were always enoxaparin. Receiving UFH at a dose of 3000 U before angiography during PCI was designed to reduce the catheter thrombosis.

Several limitations need to be showed in our study. First, this study was only performed at a single center. Second, we had a relatively small number of PCI patients in the overall and subgroup analysis, possibly resulting in insufficient power to detect significant differences between groups. The sample size of male patients in our study was approximately three times than that of female, probably restricting extrapolation of our results to female. Third, our analysis was restricted to patients with unstable angina pectoris. Larger scale studies and other patients such as acute ST-segment elevation MI should be needed in the future. Last but not least, another key limitation was that 179 patients were lost finally. Full data of MACCE were not collected during the study and the incompleteness of follow-up data availability may cause the loss of statistical power and bias of the final results.

In conclusion, our limited clinical evidence suggests that the strategy (UFH with sequential enoxaparin) may be at least as effective and safe as UFH. UFH with sequential enoxaparin has a predictable anticoagulant effect, and patients may not need repetitive ACT monitoring and no additional dose of UFH during a long time operation. When PCI patients use the transfemoral approach, we suggest that the operator take it into consideration, and the femoral artery sheath can be immediately removed after the procedure. We also recommend large-scale randomized controlled trials to verify our findings.
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